Drug intelligence / Profile preview

ZE94-0605

Development stage: Phase 1
Lead developer: Eilean Therapeutics
Modality: Small Molecules

Overview

ZE94-0605 is a preclinical, small-molecule inhibitor of cyclin-dependent kinase 2 (CDK2) being developed as an antineoplastic agent. It was initially developed by Padarn Therapeutics and is positioned to target CDK2-dependent cell-cycle progression in proliferating tumor cells, aiming to induce cell-cycle arrest and inhibit tumor growth.[1]

Targets

CDK1 (Cyclin-dependent kinase 1)CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)CDK2 (Cyclin-dependent kinase 2)

Beyond the preview

Go deeper on ZE94-0605.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZE94-0605.

Explore the full profile